Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

Oncogene volume 22, pages 7359–7368 (2003)Cite this article

Abstract

Rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20, was the first monoclonal antibody to be approved for therapeutic use. Treatment with rituximab at standard weekly dosing is effective in more than 50% of patients with relapsed or refractory CD20-positive follicular non-Hodgkin's lymphoma, but is not curative. It is less effective in other subtypes of CD20-positive lymphoma and for retreatment, even with CD20 still expressed. Thus, binding of rituximab to CD20 is not sufficient to kill many lymphoma cells, indicating that there are mechanisms of resistance. Mechanisms of cell destruction that have been demonstrated to be activated by rituximab binding to CD20 include direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity. The relative importance of each of these mechanisms in determining clinical response to rituximab treatment remains a matter of conjecture. Thus, the role of various resistance pathways, some documented in experimental systems and others still hypothetical, remains uncertain. Resistance could potentially be mediated by alterations in CD20 expression or signaling, elevated apoptotic threshold, modulation of complement activity or diminished cellular cytotoxicity. As the first of an expanding class of anticancer agents, lessons learned regarding the mechanism of rituximab action and resistance will be of increasing importance.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Alas S, Ng C-P and Bonavida B . (2002). Clin. Cancer Res., 8, 836–845.

  • Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF and Nadler LM . (1984). Blood, 63, 1424–1433.

  • Armitage JO and Weisenburger DD . (1998). J. Clin. Oncol., 16, 2780–2795.

  • Bellosillo B, Villamor N, Lopez-Guillermo A, Marce S, Esteve J, Campo E, Colomer D and Montserrat E . (2001). Blood, 98, 2771–2777.

  • Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P and Shen D . (1998). Ann. Oncol., 9, 995–1001.

  • Bladergroen B, Meijer CJLM, ten Berge RL, Hack CE, Muris JJF, Dukers DF, Chott A, Kazama Y, Oudejans JJ, van Berkum O and Kummer JA . (2002). Blood, 99, 232–237.

  • Bubien JK, Zhou LJ, Bell PD, Frizzell RA and Tedder TF . (1993). J. Cell Biol., 121, 1121–1132.

  • Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D and Reed JC . (2002). Blood, 99, 1038–1043.

  • Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, Grillo-Lopez AJ, Rosenberg J, Kunkel L and Flinn JW . (2001). J. Clin. Oncol., 19, 2153–2164.

  • Campbell KS and Colonna M . (2001). Int. Rev. Immunol., 20, 333–370.

  • Cartron G, Dacheux L, Salles G, Solal-Cellgny P and Bardos P . (2002). Blood, 99, 754–758.

  • Charles J and Foerster PAJ . (1999). Wintrobe's Clinical Hematology, Vol. 1, Chapter 44. Richard LG, John F, John L, Frixos P, John G, George MR (eds). Williams & Wilkins: Baltimore, MD, pp. 1191–1209.

    Google Scholar 

  • Clynes RA, Towers TL, Presta LG and Ravetch JV . (2000). Nat. Med., 6, 443–446.

  • Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Stamatoullas A, Milpied N, Boue F, Taillan B, Lederlin P, Najman A, Thieblemont C, Montestruc F, Mathieu-Boue A, Benzohra A and Solal-Celigny P . (2001). Blood, 97, 101–106.

  • Cragg MS, Morgan SM, Chan HTC, Morgan BP, Filatov AV, Johnson PWM, French RR and Glennie MJ . (2003). Blood, 101, 1045–1052.

  • Czuczman MS, Grillo-Lopez AJ, McLaughlin P, White CA, Saleh M, Gordon L, LoBuglio AE, Rosenberg J, Alkuzc-weny B and Maloney D . (2001). Ann. Oncol., 12, 109–114.

  • Davis TA, Czerwinski DK and Levy R . (1999). Clin. Cancer Res., 5, 611–615.

  • Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J and Levy R . (2000). J. Clin. Oncol., 17, 3135–3143.

  • Deans JP, Kalt L, Ledbetter JA, Schieven GL, Bolen JB and Johnson P . (1995). J. Biol. Chem., 270, 22632–22638.

  • Deans JP, Li H and Polyak MJ . (2002). Immunology, 107, 176–182.

  • Deans JP, Robbins SM, Polyak MJ and Savage JA . (1998). J. Biol. Chem., 273, 344–348.

  • Deans JP, Schieven GL, Shu GL, Valentine MA, Gilliland LA, Aruffo A, Clark EA and Ledbetter JA . (1993). J. Immunol., 15, 4494–4504.

  • Di Gaetano N, Xiao Y, Erba E, Bassan R, Rambaldi A, Golay J and Introna M . (2001). Br. J. Haematol., 114, 800–809.

  • Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M and Fishelson Z . (2003). Clin. Exp. Immunol., 131, 254–263.

  • Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman Jr CA and Miller TP . (1993). N. Engl. J. Med., 328, 1002–1006.

  • Foran JM, Gupta RK, Cunningham D, Popescu RA, Goldstone AH, Sweetenham JW, Pettengell R, Johnson PW, Bessell E, Hancock B, Summers K, Hughes J, Rohatiner AZ and Lister TA . (2000). Br. J. Haematol., 109, 81–88.

  • Foran JM, Norton AJ, Micallef IN, Taussig DC, Amess JA, Rohatiner AZ and Lister TA . (2001). Br. J. Haematol., 114, 881–883.

  • Friedberg JW, Neuberg D, Gribben JG, Fisher DC, Canning C, Koval M, Poor CM, Green LM, Daley J, Soiffer R, Ritz J and Freedman AS . (2002). Br. J. Haematol., 117, 828–834.

  • Ghetie M-A, Bright H and Vitetta ES . (2001). Blood, 97, 1392–1398.

  • Ghielmini M, Schmitz S-F, Cogliatti GS, Pichert G, Fey M, Betticher D, Martinelli G, Peccatori F, Hess U, Stahel R, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T, Group LW and Swiss Group for Clinical Cancer Research (SAKK). (2002). Blood, 100, A604.

  • Golay JT, Clark EA and Beverley PC . (1985). J. Immunol., 135, 3795–3801.

  • Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G and Barbui T . (2001). Blood, 98, 3383–3389.

  • Golay J, Zaffaroni L and Vaccari T . (2000). Blood, 95, 3900–3908.

  • Greenlee RT, Murray T, Bolden S and Al E . (2000). CA Cancer J. Clin., 50, 7–33.

  • Grillo-Lopez AJ . (2000). Semin. Oncol., 27, 9–16.

  • Hainsworth JD, Litchy S, Burris HA III, Scullin DC Jr, Corso SW, Yardley DA, Morrissey L and Greco FA . (2002). J. Clin. Oncol., 20, 4261–4267.

  • Harjunpaa A, Wiklund T, Collan J, Janes R, Rosenberg J, Lee D, Grillo-Lopez A and Meri S . (2001). Leukemia Lymphoma, 42, 731–738.

  • Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, DeWolf-Peeters C, Falini B and Gatter KC . (1994). Blood, 84, 1361–1392.

  • Hofmeister JK, Cooney D and Coggeshall KM . (2000). Blood Cells Mol. Dis., 26, 133–143.

  • Hooijberg E, Sein JJ, van den Berk PCM, Hart AAM, van der Valk MA, Kast WM, Melief CJM and Hekman A . (1995). Cancer Res., 55, 2627–2634.

  • Keating MJ, Flinn IW, Jain V, Binet J-L, Hillman P, Byrd JC, Albitar M, Brettman L, Santabarbara P, Wacker B and Rai KR . (2002a). Blood, 99, 3554–3561.

  • Keating MJ, O'Brien S and Albitar M . (2002b). Semin. Oncol., 29, 70–74.

  • Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, Foley PL and Taylor RP . (2003). Blood, 101, 1071–1079.

  • Kennedy GA, Tey SK, Cobcroft R, Marlton P, Cull G, Grimmett K, Thomson D and Gill D . (2002). Br. J. Haematol., 119, 412–416.

  • Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE and de Haas M . (1997). Blood, 90, 1109–1114.

  • Leonard JP and Link BK . (2002). Semin. Oncol., 29, 81–86.

  • Manches O, Lui G, Chaperot L, Gressin R, Molens J-P, Jacob MC, Sotto J-J, Lerous D, Bens J-C and Plumas J . (2003). Blood, 101, 949–954.

  • Mathas S, Rickers A, Bommert K, Dorken B and Mapara MY . (2000). Cancer Res., 60, 7170–7176.

  • McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D and Dallaire BK . (1998). J. Clin. Oncol., 8, 2825–2833.

  • O'Keefe TL, Williams GT, Davies SL and Neuberger MS . (1998). Immunogenetics, 48, 125–132.

  • Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D and Mellstedt H . (1997). J. Clin. Oncol., 15, 1567–1574.

  • Pedersen IM, Buhl AM, Klausen P, Geisler CH and Jurlander J . (2002). Blood, 99, 1314–1319.

  • Petrie RJ and Deans JP . (2002). J. Immunol., 169, 2886–2891.

  • Pichert G, Schmitz SF, Hess U, Cerny T, Cogliatti SB, Betticher D, Stupp R, Schmitter D, Stahel R and Ghielmini M . (2001). Clin. Lymphoma, 1, 293–297.

  • Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE and Jain V . (1999). Ann. Oncol., 10, 655–661.

  • Ravetch JV and Lanier LL . (2000). Science, 290, 84–89.

  • Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N and Anderson DR . (1994). Blood, 83, 435–445.

  • Sacks D and Sher A . (2002). Nat. Immunol., 3, 1041–1047.

  • Selenko N, Majdic O, Jager U, Sillaber C, Stockl J and Knapp W . (2002). J. Clin. Immunol., 22, 124–130.

  • Shan D, Ledbetter JA and Press OW . (1998). Blood, 91, 1644–1652.

  • Shan D, Ledbetter JA and Press OW . (2000). Cancer Immunol. Immunother., 48, 673–683.

  • Tedder TF, Boyd AW, Freedman AS, Nadler LM and Schlossman SF . (1985). J. Immunol., 135, 973–979.

  • Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R and Anderson KC . (2001). J. Immunother., 24, 263–271.

  • van der Kolk LE, de Haas M, Grillo-Lopez AJ, Baars JW and van Oers M . (2002). Leukemia, 16, 693–699.

  • Vose JM, Wahl RL, Saleh M and Al E . (2000). J. Clin. Oncol., 18, 1316–1323.

  • Warren TL, Dahle CE and Weiner GJ . (2000). Clin. Lymphoma, 1, 57–61.

  • Weng W-K and Levy R . (2001). Blood, 98, 1352–1357.

  • Witzig TE, Flinn IW, Gordon L and Al E . (2002a). J. Clin. Oncol., 20, 3262–3269.

  • Witzig TE, Flinn IW, Gordon LI, Emmanouilldes C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS and White CA . (2002b). J. Clin. Oncol., 20, 2453–2463.

  • Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE and Kimberly RP . (1997). J. Clin. Invest., 100, 1059–1070.

Download references

Author information

Authors and Affiliations

  1. Lymphoma Service, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, 19111, PA, USA

    Mitchell R Smith

Authors
  1. Mitchell R Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mitchell R Smith.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smith, M. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22, 7359–7368 (2003). https://doi.org/10.1038/sj.onc.1206939

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206939

Keywords

This article is cited by

Search

Advanced search

Quick links